Caroni, F.; Sammartano, V.; Pacelli, P.; Sicuranza, A.; Malchiodi, M.; Dragomir, A.; Ciofini, S.; Raspadori, D.; Bocchia, M.; Gozzetti, A.
Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies. Pharmaceuticals 2025, 18, 159.
https://doi.org/10.3390/ph18020159
AMA Style
Caroni F, Sammartano V, Pacelli P, Sicuranza A, Malchiodi M, Dragomir A, Ciofini S, Raspadori D, Bocchia M, Gozzetti A.
Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies. Pharmaceuticals. 2025; 18(2):159.
https://doi.org/10.3390/ph18020159
Chicago/Turabian Style
Caroni, Federico, Vincenzo Sammartano, Paola Pacelli, Anna Sicuranza, Margherita Malchiodi, Andreea Dragomir, Sara Ciofini, Donatella Raspadori, Monica Bocchia, and Alessandro Gozzetti.
2025. "Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies" Pharmaceuticals 18, no. 2: 159.
https://doi.org/10.3390/ph18020159
APA Style
Caroni, F., Sammartano, V., Pacelli, P., Sicuranza, A., Malchiodi, M., Dragomir, A., Ciofini, S., Raspadori, D., Bocchia, M., & Gozzetti, A.
(2025). Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies. Pharmaceuticals, 18(2), 159.
https://doi.org/10.3390/ph18020159
